Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

COVID-19 & Testosterone

Acute suppression during infection and the recovery question

Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.

The written rationale for this grade is still being prepared.

FDA
Not a product; an observed effect of SARS-CoV-2 infection

Reference only. Not medical advice.

This is something to take to a clinician. The Atlas can tell you what is known about covid-19 & testosterone in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.

Acute COVID-19 is associated with low testosterone in men, and the drop tracks with illness severity, lower testosterone correlates with higher inflammatory cytokines and worse outcomes. The likely mechanism is the effect of acute illness on the hypothalamic-pituitary-testicular axis, with possible direct testicular involvement (an estimated 10-22 percent of acutely infected men develop orchitis or epididymo-orchitis). The unresolved clinical question is recovery: most data suggest the suppression is largely a marker of acute illness, but some reports describe persistent reductions during recovery, and longer-term certainty is limited.

Testosterone falls in acute COVID, the open question is how fully it returns.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Interpreting low-T measured during/after COVID-19
  • Counseling on expected recovery
  • Distinguishing acute-illness effect from persistent hypogonadism

How it is supposed to work

Severe acute illness suppresses the hypothalamic-pituitary-testicular axis, and in COVID-19 the magnitude of testosterone decline parallels inflammatory cytokine levels. SARS-CoV-2 may also act on the testis directly, orchitis or epididymo-orchitis is reported in a notable minority, so both central (functional) and gonadal mechanisms may contribute. As an acute-illness effect, much of the suppression is expected to be transient.

Severity marker, not proven treatment target

The most useful framing is that testosterone here behaves partly as a severity marker: one longitudinal study found that the trajectory of recovering testosterone was the strongest predictor of survival among the biochemical parameters studied. That does not establish that testosterone treatment changes outcomes, correlation with severity is not the same as a treatment target, and the durability of any deficit during recovery remains an open question.

What it does to fertility

Because of possible direct testicular involvement and reported declines in fertility markers in some recovering men, transient effects on sperm parameters can occur. Evidence on long-term fertility impact is still limited and is one of the open questions; most acute suppression is expected to be reversible.

What has to be monitored

The bloodwork this needs, and the reason it belongs with a clinician rather than a website.

  • Total testosterone with LH and FSH (repeat after recovery rather than diagnosing during acute illness)
  • Semen analysis if fertility concerns persist
  • Clinical assessment for orchitis/epididymo-orchitis

What people get wrong

  • Often saidCOVID-19 permanently destroys testosterone

    ActuallyMost evidence frames the acute drop as an illness-severity effect that largely recovers; persistence during recovery is reported but long-term certainty is limited.

  • Often saidLow testosterone in COVID means you should start testosterone

    ActuallyTestosterone tracking with severity is a marker, not a proven treatment target. Levels should generally be reassessed after recovery before any diagnosis.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

At a glance

Acute pattern
Low testosterone correlates with severity and inflammation
Testicular involvement
~10-22% develop orchitis/epididymo-orchitis
Open question
Degree and durability of recovery remains uncertain

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about COVID-19 & Testosterone. A short entry is not a safe entry.

  • Timeline. We have not built the dated record of research and regulatory events.
  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.
  • What can go wrong. We have not written the risk line for this one. Read the safety section below rather than treating its absence as reassurance.
  • Where we land. We have not taken a position on this yet.

Sources

The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.

The studies that matter

  • Dhindsa et al. and related case-control work on testosterone in acute COVID-192021

    Found severely low testosterone in men with COVID-19 and an inverse relationship with severity

  • Recovery of serum testosterone levels predicts survival from COVID-19 in male patients, BMC Medicine2022

    Reported testosterone recovery trajectory as the strongest survival predictor (AUC ~92.8%) among biochemical parameters studied

  • Groti Antonic, Men, testosterone and Covid-19, Clinical Endocrinology2024

    Reviews acute suppression, possible orchitis, and uncertainty about long-term recovery